Payment overview · 2025
General Payments
$3,301.71
139 reported records · 27 companies
Healthcare provider profile · identity verified
Benjamin Abraham, DO
Allopathic & Osteopathic Physicians|Family Medicine · SNELLVILLE, GA · NPI 1538156542
Verified facts
What the public records show
CMS Open Payments records show Benjamin Abraham, DO received $3,301.71 in general payments during 2025 across 139 reported records.
Amgen Inc. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $498.25 | 15.1% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $479.54 | 14.5% | 32 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $285.05 | 8.6% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $264.83 | 8.0% | 21 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $250.59 | 7.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $237.06 | 7.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $202.92 | 6.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $182.52 | 5.5% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $151.85 | 4.6% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $139.32 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.82 | 2.5% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $74.04 | 2.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.87 | 1.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.67 | 1.5% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $49.16 | 1.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.10 | 1.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.14 | 1.3% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $28.73 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.46 | 0.9% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $23.57 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.04 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.54 | 0.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.14 | 0.6% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.08 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.20 | 0.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.17 | 0.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.05 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,211.66 | 138 |
| Education | $90.05 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $316.14 | 16 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $264.83 | 21 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $250.59 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $195.00 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $181.85 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $164.29 | 12 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $151.85 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $145.97 | 3 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $139.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $132.54 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $99.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $95.37 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $82.01 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.21 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $78.70 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $74.04 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $71.21 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.13 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.13 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $57.11 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.28 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.09 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.14 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.89 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.46 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 342 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 55 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 136 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
55 | 38 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
342 | 93 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
58 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
136 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 952 | 334 |
| Losartan Potassium | Losartan Potassium | 832 | 264 |
| Metoprolol Succinate | Metoprolol Succinate | 627 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 215 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 180 |
| Lisinopril | Lisinopril | 504 | 165 |
| Duloxetine Hcl | Duloxetine Hcl | 489 | 128 |
| Trazodone Hcl | Trazodone Hcl | 481 | 143 |
| Glimepiride | Glimepiride | 383 | 106 |
| Tramadol Hcl | Tramadol Hcl | 347 | 108 |
| Farxiga | Dapagliflozin Propanediol | 342 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 120 |
| Prednisone | Prednisone | 306 | 170 |
| Hydralazine Hcl | Hydralazine Hcl | 232 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 74 |
| Pregabalin | Pregabalin | 202 | 58 |
| Famotidine | Famotidine | 199 | 76 |
| Torsemide | Torsemide | 181 | 61 |
| Eliquis | Apixaban | 178 | 43 |
| Metformin Hcl Er | Metformin Hcl | 177 | 65 |
| Potassium Chloride | Potassium Chloride | 176 | 62 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 172 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 170 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 47 |
| Bupropion Xl | Bupropion Hcl | 163 | 42 |
| Bumetanide | Bumetanide | 162 | 44 |
| Gabapentin | Gabapentin | 162 | 70 |
| Omeprazole | Omeprazole | 158 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 67 |
| Mirtazapine | Mirtazapine | 144 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 136 | 46 |
| Valsartan | Valsartan | 135 | 36 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 132 | 35 |
| Ozempic | Semaglutide | 131 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 60 |
| Carvedilol | Carvedilol | 128 | 45 |
| Finasteride | Finasteride | 121 | 39 |
| Celecoxib | Celecoxib | 112 | 38 |
| Xarelto | Rivaroxaban | 111 | 30 |
| Meloxicam | Meloxicam | 110 | 45 |
| Nifedipine Er | Nifedipine | 108 | 37 |
| Buspirone Hcl | Buspirone Hcl | 103 | 27 |
| Furosemide | Furosemide | 103 | 37 |
| Metformin Hcl | Metformin Hcl | 99 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 36 |
| Alendronate Sodium | Alendronate Sodium | 96 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 31 |
| Allopurinol | Allopurinol | 89 | 26 |
| Simvastatin | Simvastatin | 77 | 26 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 76 | 20 |
| Sertraline Hcl | Sertraline Hcl | 75 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 25 |
| Synthroid | Levothyroxine Sodium | 69 | 25 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 68 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 28 |
| Glipizide | Glipizide | 56 | 19 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Prolia | Denosumab | 55 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 17 |
| Gemtesa | Vibegron | 51 | 12 |
| Ketoconazole | Ketoconazole | 51 | 36 |
| Methimazole | Methimazole | 49 | 11 |
| Roflumilast | Roflumilast | 44 | suppressed |
| Calcitriol | Calcitriol | 43 | 11 |
| Myrbetriq | Mirabegron | 43 | 15 |
| Spironolactone | Spironolactone | 43 | 14 |
| Atenolol | Atenolol | 42 | 14 |
| Ezetimibe | Ezetimibe | 42 | 18 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 39 | 39 |
| Aripiprazole | Aripiprazole | 39 | 11 |
| Cefuroxime | Cefuroxime Axetil | 39 | 36 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 37 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 37 | 11 |
| Risperidone | Risperidone | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 15 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 32 |
| Kerendia | Finerenone | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 13 |
| Topiramate | Topiramate | 31 | 13 |
| Mounjaro | Tirzepatide | 30 | 12 |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 14 |
| Meclizine Hcl | Meclizine Hcl | 29 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 23 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Azelastine Hcl | Azelastine Hcl | 25 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | 16 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 23 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 19 |
| Glipizide Er | Glipizide | 22 | 11 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Metolazone | Metolazone | 20 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,301.71 · 139 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, Evoke, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GARDASIL 9, GEMTESA, INGREZZA, INSPIRE, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, Prospera, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TONMYA, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, V.A.C. VERAFLO, V.A.C.ULTA, VRAYLAR, VYNDAQEL, Veozah, WATCHMAN Access System, Wegovy | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error